Kornimate/medical-research-clean huggingface dataset:
removal of urinary catheter after radical surgery

Conditions: Cervical Cancer; Radical Hysterectomy; Bladder Dysfunction

Summary: currently, the treatment of cervical cancer in early stages is performed with a radical surgery called radical hysterectomy with pelvic lymphadenectomy. this surgery, when indicated correctly, in early stages of this disease, has a cure rate of approximately 90% at 5 years, compared to the same pelvic radiotherapy. however, it is known that most patients with early stage cervical cancer are young (average age 45) and treating these patients with radiotherapy would have a loss of hormonal function by damage to the ovaries and damage in sexual function by radiotherapy effects in the vagina. furthermore, if the patient has a pelvic recurrence, the option of radiotherapy treatment could not be offered. due to the factors listed above, nowadays, in young patients with good clinical conditions and tumors in early stages, radical surgery is a good option. in this radical surgery there is a need for removal of the parametrium, and different degrees of pelvic denervation may occur causing damage of urinary function.currently, there is no consensus about the correct moment of catheter removal and evaluation of urinary function using the residual urine test. while in some services the urinary catheter is removed on day 1 postoperatively, in others it is removed on the 14th day postoperatively. for these reasons, this study aims to compare the early catheter removal (day 1 postoperatively) versus standard in the investigator's service (7 days postoperatively) withdrawal. if this study detect that the patients may remove the urinary catheter on day 1 postoperatively, much less cost, discomfort, pain and comorbidities associated with the use of indwelling catheter for prolonged periods occur, such as urinary tract infection, use of antibiotics and even hospitalization for this reason.


Eligibility criteria:
inclusion criteria: * the inclusion criteria for this study are women with invasive cervical neoplasia treated with hysterectomy or radical trachelectomy exclusion criteria: * patients treated at another cancer service.
home remineralization of white spot lesions with two different toothpastes.

Conditions: White Spot Lesion

Summary: the aim of the study is to compare white spot lesions before, during and after treatment with new biorepair advanced sensitive toothpaste containing micro crystals of hydroxyapatite and colgate toothpaste with 1450 ppm of fluoride. the timeline will consider the study begin, 15 days, 30 days and 90 days after the beginning of the study. the following indices will be recorded: bewe index, schiff air index, vas scale. after that, patients will fill in a satisfaction questionnaire.

the aim of the study is to compare white spot lesions before, during and after treatment with two different toothpastes for home oral care. patients who agree to sign the informed consent will be randomly assigned to two different groups: * trial group will use new biorepair advanced sensitive toothpaste containing micro crystals of hydroxyapatite; * control group will use colgate toothpaste with 1450 ppm of fluoride. at the baseline, professional oral hygiene will be performed. the following indices will be recorded at the study begin and at the following 15, 30 and 90 days: bewe index, schiff air index, vas scale. after that, patients will fill in a satisfaction questionnaire.

Eligibility criteria:
inclusion criteria: * patients with white spot lesions; * patients with dental sensibility; * adult patients; * patients that sign the informed consent to participate to the study. exclusion criteria: * patients with low compliance or motivation to participate to the study; * patients not presenting white spot lesions; * patients with absence of dental sensibility; * patients pregnant or breastfeeding; * underage patients; * patients with psychiatric diseases.

Keywords: remineralization hydroxyapatite
safety and efficacy trial evaluating the use of sr34006 in the treatment of deep vein thrombosis (dvt)

Conditions: Deep Vein Thrombosis

Summary: patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. the purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, sanorg34006, with the standard way of treating deep vein thrombosis. the standard treatment includes injections or infusions of an anticoagulant drug (unfractionated heparin or low molecular weight heparin) for about a week, followed by vitamin k antagonist (vka) anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. eligible patients will be assigned to treatment with either sanorg34006 or the combination of unfractionated heparin or low molecular weight heparin plus a vka (warfarin or acenocoumarol) by random chance. treatment will be known to both patients and their doctors.


Eligibility criteria:
inclusion criteria: * confirmed acute symptomatic dvt * written informed consent exclusion criteria: * legal lower age limitations * patients with symptomatic pulmonary embolism * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of dvt * other indication for vka than dvt * more than 36 hours before the treatment with therapeutic dosages of low molecular weight heparin or initiation of vka treatment prior to randomization * participation in another pharmacotherapeutic study within the prior 30 days * creatinine clearance \<10ml/min, severe hepatic disease or bacterial endocarditis * life expectancy \<3 months * active bleeding or high risk for bleeding * uncontrolled hypertension: systolic blood pressure \>180 mm hg and diastolic blood pressure \>110 mm hg. * pregnancy or childbearing potential without proper contraceptive measures * any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin (ufh), enoxaparin, or tinzaparin
duodenal tissue resection acquisition (direct) study

Conditions: Duodenum Disease

Summary: to evaluate the quality of cold snare resection specimens of duodenal mucosa tissue in patients undergoing an upper gastrointestinal interventional endoscopy in order to improve the processing of histological samples and its assessment in general and for future duodenal ablation studies.

the duodenum plays an important role in metabolic health. there is evidence that the duodenal mucosa undergoes certain histological changes in the development of features of the metabolic syndrome and ultimately type 2 diabetes (t2d). to date, it is not known exactly what type of histological changes the duodenal mucosa undergoes in t2d, so elucidating these changes may lead to a better understanding and potentially new treatment options for metabolic syndrome and t2d. the assessment of histological changes in tissue obtained from duodenal biopsies has proven to be very difficult due to the lack of orientation in the histological slides obtained. the investigators have learned that duodenal biopsies are too small and superficial to reliably assess histological changes in the duodenal mucosa and submucosa. currently, the investigators are taking small cold snare resections from the duodenum to try to fully assess the duodenal (sub)mucosa. however, the investigators still have problems with the orientation of these resections. when slides are made, the specimens are curled, cut tangentially and artefacts occurr. as a result, it is still not possible to make a proper assessment of the duodenal (sub)mucosa. therefore, the investigators aim to optimise the process of obtaining, storing, processing and staining the duodenal mucosal tissue samples from cold snare resections. the investigators plan to optimise this process in patients who have already undergone upper gastrointestinal interventional endoscopy, including ablation therapy, endoscopic submucosal dissection (esd) or endoscopic mucosal resection (emr) for barrett's neoplasia and squamous cell carcinoma of the oesophagus or small gastric neoplasia, or oesophageal dilatations, as the endoscopist performing dmr in the netherlands also specialises in these endoscopic treatments. by studying the process of obtaining duodenal mucosal tissue samples in this specific patient population, there is no need to expose other patients to an upper gastrointestinal endoscopy with the associated propofol sedation.

Eligibility criteria:
inclusion criteria: * already scheduled to undergo an upper gastrointestinal interventional endoscopy * endoscopy under deep sedation (propofol) in amsterdam umc exclusion criteria: * previous gi surgery that could affect the ability to reach the duodenum via endoscopy, such as bilroth 2, roux-en-y gastric bypass, or other similar procedures or condition * history of duodenal inflammatory diseases including crohn's disease and celiac disease
role of the oral microbiome in blood pressure regulation in pregnancy

Conditions: Gestational Hypertension

Summary: high blood pressure in pregnancy is associated with poor outcomes for both mum and baby, increasing the risk of pregnancy complications including pre-eclampsia, fetal growth restriction and preterm birth. the development of new blood pressure lowering interventions suitable for use in pregnancy is a key research priority. inorganic nitrate is a compound found in certain types of food, particularly green leafy vegetables and beetroot. nitrate provides an important source of nitric oxide (no), a molecule involved in keeping blood vessels healthy and regulating blood pressure. supplementation with nitrate in the diet, using interventions such as beetroot juice, has been shown to reduce blood pressure and improve blood vessel function. in order for dietary nitrate to have these beneficial effects, it needs to be converted in the body to nitrite, via bacteria that live in the mouth (oral bacteria). differences in oral bacteria, and how they metabolise nitrate, are thought to influence blood pressure regulation and potentially response to dietary nitrate supplementation. this study aims to understand (1) whether pregnant women with high blood pressure have a different composition of oral bacteria compared to healthy pregnant women and women who are not pregnant, and (2) how differences in oral bacteria affect blood pressure responses to a dose of dietary nitrate (in the form of beetroot juice).


Eligibility criteria:
inclusion criteria: * normotensive or hypertensive women (hypertension as systolic blood pressure \>140 mmhg and/or diastolic blood pressure \>90 mmhg or on anti-hypertensive medication) * for pregnant women, between 20-28 weeks gestation exclusion criteria: * multi-fetal pregnancy (for pregnant women) * age under 16, or over 45 years of age * lacking ability to consent * pre-existing diabetes (type 1/type 2) * previous history of pre-term fgr (delivery before 32 weeks with fgr) * current tobacco smoker * body mass index greater than or equal to 40 or less than or equal to 18 * use of any of the following drugs in the last 6 months: systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral) * large doses of commercial probiotics (greater than or equal to 108 cfu or organisms per day) including tablets, capsules, lozenges, chewing gum or powders (ordinary dietary components such as yoghurts do not apply) * evidence of oral disease, assessed on screening proforma (current conditions of: oral candidiasis (thrush); dental caries (tooth decay); halitosis; oral ulcerations/mouth ulcers; wisdom tooth pain; chronic dry mouth) * allergy to beetroot juice or lemon juice (both contained within the juice shot)

Keywords: pregnancy hypertension nitrate beetroot juice
promoting flu vaccination through a mobile wellness program

Conditions: Not Condition-specific

Summary: the investigators design a 6-week messaging campaign aimed at promoting flu vaccination among fully insured members of a national payer that participate in a wellness program offered by the insurer through a mobile app. outcomes measured will include uptake in flu vaccination rate as measured by the insurer and engagement with the campaign through the app. the goal of the research is to assess the effectiveness of pervasive computing messaging in promoting preventative care treatments such as flu shots. an additional goal is that of quantifying the importance of emphasizing incentives to increase efficacy of the messages.


Eligibility criteria:
inclusion criteria: * belongs to fully insured population * continuous health coverage between january 1, 2015 and june 1, 2016 * has downloaded and installed the wellness platform app exclusion criteria: * has declined the messaging from the platform
effectiveness of the combination of water aerobics and metacognitive training

Conditions: Psychosis

Summary: the objective of this study is to assess the efficacy of a combined intervention of water aerobics and metacognitive training (mct), compared to each intervention separately, in people with psychosis. one purpose is to analyze the improvement of clinical, cognitive, metacognitive and psychosocial variables, motor coordination and physical health condition. another purpose is to study the changes in sp1 and sp4 biomarker transcription levels as a function of the intervention received. the hypothesis is that the combined intervention will enhance the benefits of each intervention separately, specifically in symptoms, cognition, metacognition and psychosocial variables.


Eligibility criteria:
inclusion criteria: * presence of one of the following diagnoses according to dsm-v criteria: schizophrenia, unspecific psychotic disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder. * psychopatological stability * 18 to 55 years old * interested in participating in both water aerobics and mct groups exclusion criteria: * head injury or intellectual disabillity (premorbid iq \<=70) * present scores on the panss \>=5 in hostility, lack of cooperation or suspiciousness, to guarantee a good relationship in the group * patients with substance dependence disorder * problems related to water activities (phobia, severe mobility problems...)
medtronic concomitant utilization of radio frequency for atrial fibrillation cure-af/persistent

Conditions: Atrial Fibrillation

Summary: this investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with atrial fibrillation (af) requiring concomitant open heart surgery plus the cardioblate surgical ablation system using the modified maze iii procedure. the trial population includes patients requiring valve replacements or repairs, atrial septal defect (asd) repairs, patent foramen ovale (pfo) closure or coronary artery bypass graft (cabg) procedures. the study objectives are to demonstrate that the medtronic cardioblate surgical ablation system can safely and effectively treat persistent af patients.


Eligibility criteria:
inclusion criteria: 1. patients must have a documented history of persistent af as defined by the acc/aha/esc guidelines: characterized as episodes of non-self-terminating atrial fibrillation that usually lasts more than 7 days. 2. concomitant indication (other than af) for open-heart surgery for one or more of the following: * mitral valve repair or replacement * aortic valve repair or replacement * tricuspid valve repair or replacement * atrial septal defect (asd) repair * patent foramen ovale (pfo) closure * coronary artery bypass procedures 3. greater than or equal to 18 years of age 4. able and willing to comply with study requirements by signing a consent form 5. must be able to take the anticoagulant warfarin (coumadin) exclusion criteria: 1. wolff-parkinson-white syndrome 2. nyha class = iv 3. left ventricular ejection fraction ≤ 30% 4. need for emergent cardiac surgery (i.e. cardiogenic shock) 5. previous atrial ablation for af, av-nodal ablation, or surgical maze procedure 6. contraindication for anticoagulation therapy 7. left atrial diameter \> 7.0 cm 8. preoperative need for an intra-aortic balloon pump or intravenous inotropes 9. renal failure requiring dialysis or hepatic failure 10. life expectancy of less than one year 11. pregnancy or desire to be pregnant within 12 months of the study treatment. 12. current diagnosis of active systemic infection 13. documented mi 6 weeks prior to study enrollment

Keywords: persistent atrial fibrillation surgical rf ablation perisistent atrial fibrillation surgical ablation
feasibility and efficacy of the ketogenic diet in alzheimer's disease

Conditions: Alzheimer Disease

Summary: the purpose of the kdraft study is to assess the feasibility and preliminary cognitive efficacy of a ketogenic diet therapy in patients with alzheimer's disease.


Eligibility criteria:
inclusion criteria: * alzheimer's disease (cdr 0.5, 1, \& 2) * active study partner * bmi \> 21 * english speaking exclusion criteria: * bmi \< 21 * consume greater than 14 drinks of alcohol per week * insulin dependent diabetes mellitus * diagnosis of active cancer * myocardial infarction or symptoms of coronary artery disease (e.g. angina) in last year

Keywords: ketogenic diet alzheimer's disease
efficacy and safety of xp12b in women with menorrhagia

Conditions: Menorrhagia; Heavy Menstrual Bleeding

Summary: the purpose of this study is to determine whether xp12b is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.


Eligibility criteria:
inclusion criteria: * women with menorrhagia * 18-49 years of age * regularly occurring menstrual periods exclusion criteria: * history or presence of clinically significant disease or abnormalities that may confound the study * history of bilateral oophorectomy or hysterectomy * hormone therapy for birth control

Keywords: menorrhagia heavy menstrual bleeding
pk study of liquid formulation of bio89-100 in subjects with nash with compensation cirrhosis

Conditions: NASH - Nonalcoholic Steatohepatitis

Summary: this is an open-label, single-dose study to evaluate the pk profile of the liquid sc formulation of bio89-100 in approximately 8 male and female subjects with nash with compensated cirrhosis.


Eligibility criteria:
key inclusion criteria: * age 21 to 65 * diagnosis of nash with compensated cirrhosis by a hepatologist based on liver forum criteria. * model for end-stage liver disease (meld) score \< 12. * child-turcotte-pugh (ctp) score \< 7 (class a). * fibrosis stage f4 by fibroscan. key exclusion criteria: * history of hepatic cirrhosis decompensation, or overt hepatic encephalopathy or signs of hepatic cirrhosis decompensation. * prior transjugular intrahepatic portosystemic (tips) shunt procedure. * known condition other than cirrhosis that may possibly interfere with drug absorption, distribution, metabolism, or excretion. * significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening.
exploratory analysis of enhanced liver function (elf) test to detect early fatty liver in high risk population

Conditions: Fatty Liver

Summary: in this initial investigator-initiated retrospective study, aim to analyze the enhanced liver fibrosis (elf) scores in this high-risk population for nafld/nonalcoholic steatohepatitis(nash)-related fibrosis. study define 'high-risk' to include metabolic syndrome, which can be further defined by an atherosclerotic cardiovascular disease (ascvd) score \>7.5, any diagnosis of hyperlipidemia, history of coronary artery disease, history of heart failure, hypertension and/or type 2 diabetes. study would also like to compare the performance of this score with historical methods of fibrosis assessment, where applicable, including vibration-controlled transient elastography, magnetic resonance elastography, blood markers and liver biopsy. study will assess the impact of elf scores on predicting liver events in the time, have used it and determine if diet, lifestyle changes and/or pharmacotherapy will improve serial elf scores. will also seek to understand how elf scores are distributed in our community.

methodist health system consists of nine hospitals and over one hundred clinics that serve 7% to 10% of patients in the dallas metropolitan. in november 2021, adopted the use of elf tests in patients who had risk factors for nafld/nash based on abnormal liver enzymes, metabolic risk factors, and evidence of hepatosteatosis on imaging. there is a knowledge gap in the literature when it comes to elf scores in our population and the data we collect in this study will contribute to filling that knowledge gap. historically, assessment of fibrosis has been accomplished with fibroscan,elastography or liver biopsy. however, these tests are not widely available in most clinics, and can be invasive and costly. at present, the two primary inexpensive and non-invasive alternatives are the fibrosis-4 (fib-4) and elf scores, which employ algorithms that utilize routine lab draws. while a low fib-4 score has a negative predictive value of 90% for advanced fibrosis, it does not provide a risk assessment of liver-related events. for this reason, the study explore the newer elf serum test as a non-invasive, more affordable and available means to detect patients with developing fibrosis and as a predictor of liver-related outcomes that could be easily used in a primary care setting. this will better risk-stratify this patient population at the primary care level, without need for invasive and expensive testing, and will guide appropriate referrals to hepatology.

Eligibility criteria:
inclusion criteria: * age: ≥ 18 years * nafld/nash and non-nafld/nash patients who have had an assessment with elf score at methodist dallas medical center from november 2021 to december 2023. exclusion criteria: * patients with incomplete data and those lost to follow up.
effect of vagus nerve stimulation on chronic stroke patients

Conditions: Stroke

Summary: stroke is still one of the top causes of death and adult-onset disability in the world. despite physiotherapy and rehabilitation, a sizable percentage of chronic stroke patients are permanently disabled. these neurological deficiencies include cognitive impairment, sensory impairment, loss of coordination, spasticity, dysphasia, dysphagia, visual field dysfunction, and weakness.

exercises, neurophysiological and electrical stimulations, compensatory strategies, strengthening facilitation approaches programs, and programs are all used as general approach methods in the rehabilitation of stroke patients. transcutaneous stimulation of the vagus nerve offers non-invasive stimulation of the vagus nerve and is commonly carried out by stimulating the auricular vagus nerve in the ear or transcutaneous cervical branch vagus in the neck.

Eligibility criteria:
inclusion criteria: * to be between the ages of 18-80. * having been diagnosed with a stroke by a neurologist. * speech disorder after a cerebrovascular accident to be. * to volunteer to participate in the study. exclusion criteria: * being mentally affected (mini-mental test score \<24). * having other neurological diseases other than stroke. * concomitant symptoms that prevent individuals from participating in the study (having undergone amputation surgery, having cardiac arrhythmias be etc.)